Tag:

Arena Pharmaceuticals

Latest Headlines

Latest Headlines

Vivus, Arena hope Aetna weight-management program boosts diet-drug sales

Both Vivus and Arena marketing partner Eisai have partnered with healthcare benefits provider Aetna, which will integrate rival obesity drugs Qsymia and Belviq into a weight-loss lifestyle pilot program.

Orexigen shares soar as long-delayed weight drug clears PhIII safety hurdle

More than two years after Orexigen began a forced march back through a $100 million Phase III study for its weight drug Contrave, the biotech is back with the news that it scored the positive interim results it needs for a return trip to the FDA. And the drug developer says it can look ahead to a potential approval as early as June, 2014.

Eisai bets another $60M on Arena's Belviq with worldwide marketing deal

Eisai gave Arena Pharmaceuticals' obesity drug Belviq another vote of confidence. The Japanese drugmaker, already marketing the drug in the U.S., signed up to promote it in most other global markets, too. And it gave Arena a $60 million up-front payment to seal the deal.

Eisai to recruit 200 new sales reps for amped-up Belviq push

Analysts promised a battle of obesity drugs between Arena's Belviq and Vivus' Qsymia. But in marketing partner Eisai, Arena has a weapon Vivus lacks--and that weapon is about to get bigger. The Japanese company plans to add more than 200 sales reps to its army by December, doubling its size since the drug hit the market this June.

Broker's Facebook rant on biotech stock draws $5K fine

A stockbroker who took to his Facebook page to sound off in reaction to a critical online report last year regarding Arena Pharmaceuticals has been fined $5,000 for the outburst via social media.

Expect a long slog for diet drugs Qsymia, Belviq

Vivus says its new diet drug Qsymia is now available in 8,000 retail pharmacies, putting it closer to patients. Arena Pharmaceuticals' Belviq is finally on the market, and scripts are coming in. But this new generation of weight-loss pills still faces an uphill climb--despite the tantalizing size of the market.

Battle of weight-loss drugs begins as Arena launches Belviq next week

The long-awaited battle between two weight loss drugs is ready to begin. With its launch for Belviq delayed by the DEA, Arena has had to sit back and watch competitor Vivus pass it by with its own weight-loss drug. Now, nearly a year after the FDA cleared Belviq for approval, investors will get the chance to see if it can outperform its underwhelming competitor, Qsymia.

DEA finally acts on Belviq, clearing Arena for diet drug's launch

The DEA has made its decision on Belviq, the weight-loss drug that's been sitting on Arena's launching pad since its FDA approval last June. Belviq is now officially a Schedule IV controlled substance, and Arena can fire up its engines for a launch next month.

Arena pulls app for weight-loss drug Belviq in EU

Arena Pharmaceuticals has decided to take its drug application and go home. The drugmaker Friday said it was giving up for now on breaking through the European wall of resistance to its weight-loss drug Belviq. The company, which got FDA approval last year, yanked its application with little explanation.

UPDATED: Arena shares sink after biotech withdraws marketing app for obesity drug in Europe

Arena Pharmaceuticals pulled the plug on its application for approval of the obesity drug Belviq with European regulators, another blow to the commercial and regulatory effort behind the treatment. The San Diego-based biotech revealed the decision to withdraw the app in its first-quarter financial report late Thursday afternoon.